ACTA1 and neoplasm: However, reducing tumour collagen production by deleting Col1a1 in αSMA-expressing cells or upon treatment with anti–lysyl oxidase like-2 antibody accelerated progression of pancreatic cancer20,21, suggesting that a collagen-rich ECM may also have tumour-protecting functions.